1-3 of 3
Ivana Teodorovic
Close
Sort by
Journal Articles

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Clinical Trials & Observations
Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, Anton Hagenbeek
Journal: Blood
Blood (2006) 108 (10): 3295–3301.
https://doi.org/10.1182/blood-2006-05-021113
Published: 2006
Journal Articles

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, PhD, Ivana Teodorovic, MD, Cynthia Rozewicz, Richard Klasa, MD, Robert E. Marcus, MD, Max Wolf, MD, Eva Kimby, MD, Anton Hagenbeek, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 353.
https://doi.org/10.1182/blood.V106.11.353.353
Published: 2005
Journal Articles

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraâ) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma : A Phase III Randomized Intergroup Clinical Trial.

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Ivana Teodorovic, MD, Cynthia Rozewicz, Richard Klasa, MD, PhD, Robert E. Marcus, Max Wolf, MD, Eva Kimby, MD, Anton Hagenbeek, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 586.
https://doi.org/10.1182/blood.V104.11.586.586
Published: 2004